Real-world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system.

ABSTRACT:

Background

We evaluated the frequency of genomic testing and treatment patterns by age category in patients with newly diagnosed (ND) acute myeloid leukemia (AML) treated in both academic- and community-based health systems within a single Midwestern State.

Methods

Retrospective analysis of data from the Indiana University Health System Enterprise Data Warehouse and two local cancer registries, of 629 patients aged ≥18 years with ND AML during 2011-2018. Primary outcome variables were, proportion of patients with genomic analysis and frequency of mutations. Chemotherapy was categorized as "standard induction" or "other chemotherapy"/targeted therapy, and hypomethylating agents.

Results

Overall, 13% of ND AML patients between 2011 and 2018 had evidence of a genomic seq

SUBMITTER: Byrd JC 

PROVIDER: S-EPMC10524030 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature